If your doorstep, like those of millions of Americans, was graced with an Amazon package this year, you may have thought about the data behind the delivery. But when the company is not only delivering, but developing and deploying, a COVID-19 diagnostic test, that data movement becomes relevant to our interoperability discussions. This week we heard from colleagues at Amazon discuss their findings.

The Reagan-Udall Foundation for the FDA (FDA Foundation) also announced the availability of funds to support studies of the real-world performance of two types of COVID-19 diagnostic tests. The purpose of this research is to evaluate real-world performance for two types of diagnostic tests (antigen and molecular) and to determine how RWD/RWE can be leveraged for Emergency Use Authorizations (EUA) or full market approvals (FMA). For more information or to apply please visit the funding announcement's webpage.

This is the once-monthly COVID-19 Evidence Accelerator Diagnostics Lab Meeting. These meetings occur the third Thursday of every month at 12 pm ET. 

If you are interested in attending the meeting series please email us at evidenceaccelerator@reaganudall.org.